Supplementing with NAD+ may help support mitochondrial function, cellular repair mechanisms, and overall energy metabolism
Planteamiento diagnstico de la colitis isqumica
In the U.S., approximately 38.4 million people, or 11.6% of the population , have diabetes, with millions more pre-diabetic or overweight, creating a large pool of potential GLP-1 users
Most patients see meaningful weight loss within 68 weeks and continued improvement over 12 months of consistent use
More than 75% of patients experience at least one side effect, with nausea, constipation, diarrhea, and vomiting being the most frequently reported ^2
Existing GSDMD covalent inhibitors (disulfiram, necrosulfonamide, dimethyl fumarate) all target Cys191, but their impact on palmitoylation is unknown, highlighting the potential of developing palmitoylation-site-specific modulators for IBD (186188)